← Leaderboards
Warren D Kruger
Fox Chase Cancer Center
$13,003,109
Attributed
$13,003,109
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $895.3K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,003,109 · 8
By mechanism
R01$12,597,302 · 6
R21$340,000 · 1
R29$65,807 · 1
Top collaborators
No co-investigators on record.
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Paul F. Engstrom$18,067,774
- Irma H. Russo$1,199,771
- Louis M Weiner$35,160,146
- Jose Russo$20,321,995
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAffectLeadMethionineHomocysteineMutationPhenotypeMouse ModelPathway InteractionsNovel StrategiesAllelesIn VivoAnimalsEnzymesCystathionine Beta-SynthaseGene ExpressionEnzyme ActivityPlasmaMalignant NeoplasmsPlayGenesResearch StudyInsightCells
Grant awards (37)
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer$406,375
R01 · FY2024 · CA · contact PI
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer$419,207
R01 · FY2023 · CA · contact PI
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer$419,207
R01 · FY2022 · CA · contact PI
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer$427,763
R01 · FY2021 · CA · contact PI
Treatment of CBS deficiency with proteostasis modulators$467,500
R01 · FY2020 · DK · contact PI
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer$427,763
R01 · FY2020 · CA · contact PI
Treatment of CBS deficiency with proteostasis modulators$467,500
R01 · FY2019 · DK · contact PI
Treatment of CBS deficiency with proteostasis modulators$457,500
R01 · FY2018 · DK · contact PI
Treatment of CBS Deficiency with Proteostasis Modulators$407,175
R01 · FY2017 · DK · contact PI
Treatment of CBS Deficiency with Proteostasis Modulators$397,163
R01 · FY2016 · DK · contact PI
Treatment of CBS Deficiency with Proteostasis Modulators$397,163
R01 · FY2015 · DK · contact PI
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics$339,150
R01 · FY2015 · GM · contact PI
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics$100,000
R01 · FY2015 · GM · contact PI
Treatment of CBS Deficiency with Proteostasis Modulators$397,163
R01 · FY2014 · DK · contact PI
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics$339,150
R01 · FY2014 · GM · contact PI
The Role of Methylthioadenosine Phosphorylase Loss in Tumorigenesis$337,720
R01 · FY2013 · CA · contact PI
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics$327,280
R01 · FY2013 · GM · contact PI
The Role of Methylthioadenosine Phosphorylase Loss in Tumorigenesis$358,605
R01 · FY2012 · CA · contact PI
Hyperhomocysteinemia, S-adenosylhomocysteine Accumulation, and Epigenetics$338,676
R01 · FY2012 · GM · contact PI
The Role of Methylthioadenosine Phosphorylase Loss in Tumorigenesis$351,225
R01 · FY2011 · CA · contact PI
The Role of Methylthioadenosine Phosphorylase Loss in Tumorigenesis$362,088
R01 · FY2010 · CA · contact PI
Genetic Modulation of CBS to Lower Plasma Homocysteine$415,103
R01 · FY2009 · HL · contact PI
The Role of Methylthioadenosine Phosphorylase Loss in Tumorigenesis$361,742
R01 · FY2009 · CA · contact PI
Genetic Modulation of CBS to Lower Plasma Homocysteine$415,103
R01 · FY2008 · HL · contact PI
Genetic Modulation of CBS to Lower Plasma Homocysteine$415,103
R01 · FY2007 · HL · contact PI
COX-2 and PPARgamma: Targets for BRCA Prevention$262,798
R01 · FY2007 · CA · contact PI
Genetic Modulation of CBS to Lower Plasma Homocysteine$427,500
R01 · FY2006 · HL · contact PI
COX-2 and PPARgamma: Targets for BRCA Prevention$270,647
R01 · FY2006 · CA · contact PI
COX-2 and PPARgamma: Targets for BRCA Prevention$277,570
R01 · FY2005 · CA
GENETIC MODULATION OF CBS TO LOWER PLASMA HOMOCYSTEINE$378,000
R01 · FY2004 · HL
COX-2 and PPARgamma: Targets for BRCA Prevention$278,800
R01 · FY2004 · CA
GENETIC MODULATION OF CBS TO LOWER PLASMA HOMOCYSTEINE$378,000
R01 · FY2003 · HL
Effect of Hepatotoxins &Adomet on Liver Gene Expression$170,000
R21 · FY2003 · AA
GENETIC MODULATION OF CBS TO LOWER PLASMA HOMOCYSTEINE$383,250
R01 · FY2002 · HL
Effect of Hepatotoxins &Adomet on Liver Gene Expression$170,000
R21 · FY2002 · AA
GENETIC MODULATION OF CBS TO LOWER PLASMA HOMOCYSTEINE$388,313
R01 · FY2001 · HL
RISK OF VASCULAR DISEASE IN CBS HETEROZYGOTES$65,807
R29 · FY2000 · HL